{"schema_version":"secwatch.filing_event.v1","accession":"0001739410-25-000108","form_type":"8-K","ticker":"RLYB","cik":"0001739410","company_name":"Rallybio Corp","filed_at":"2025-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.847717+00:00","generated_at":"2026-05-17T17:57:50.567044+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Rallybio Q2 net loss $9.7M, sells REV102 to Recursion for $25M; RLYB116 data Q3/Q4 2025","bullets":["Net loss of $9.7M ($0.22/share) vs $16.2M in Q2 2024; revenue $0.2M.","Sold REV102 to Recursion for up to $25M, including $7.5M upfront equity; cash runway extended into mid-2027.","RLYB116 confirmatory PK/PD study dosing started; Cohort 1 and Cohort 2 topline data expected Q3 and Q4 2025.","RLYB212 program discontinued after Phase 2 PK data missed target concentrations.","Cash, equivalents and marketable securities $45.7M at June 30, 2025; with REV102 payment, runway into mid-2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001739410-25-000108","json":"https://secwatch.observer/filing/0001739410-25-000108.json","markdown":"https://secwatch.observer/filing/0001739410-25-000108.md","text":"https://secwatch.observer/filing/0001739410-25-000108.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1739410/000173941025000108/0001739410-25-000108-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1739410/000173941025000108/rlyb-20250807.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T17:57:50.567044+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}